Ilias A, et al. - In this prospective observational study, researchers assessed the impacts of a reverse switch (from a biosimilar to Remicade) in a real-life cohort. The study sample consisted of 174 unselected and consecutive patients with inflammatory bowel diseases (IBD) who received maintenance therapy with the biosimilar in Hungary. Data were collected from a real-life cohort of subjects with Crohn’s disease or ulcerative colitis who were switched from maintenance therapy with a biosimilar to Remicade or were treated with only Remicade. No significant changes have been noted in patients switching from biosimilar to Remicade in remission, trough levels, or anti-drug antibodies. There have been no new safety signals detected.